CD8A and glioblastoma: We next characterized the CD8 T cells populating GBM tumors, and found a modest increase in CD62L-CD44+ effector cells in anti-VEGF-treated tumors, which were significantly expanded upon dual therapy compared with untreated and IM-monotherapy arms (Figure 2A).